Tag: Ocugen

The biotechnology sector has witnessed the emergence of a standout performer: Ocugen. This gene therapy enterprise is demonstrating remarkable momentum, ...

Gene therapy specialist Ocugen delivered a brutal shock to investors this week, with its shares plummeting amid growing concerns about ...

The biotechnology sector offers little mercy to struggling companies, and Ocugen finds itself in precisely that position. With investor confidence ...

The biotech firm Ocugen finds itself at the center of a storm, presenting investors with a perplexing mix of encouraging ...

The U.S. Food and Drug Administration has removed the clinical hold on Ocugen's promising ocular therapeutic candidate OCU200, clearing the ...

The biotechnology sector is watching Ocugen with keen interest as the company makes waves with its bold strategic vision. At ...

A prolonged regulatory standoff with U.S. health authorities has concluded favorably for Ocugen. The biopharmaceutical company announced that the Food ...

After an extended period of lateral trading, shares of biotechnology firm Ocugen are attracting renewed market interest. The catalyst appears ...

Pennsylvania-based biotech firm Ocugen captured significant market attention on Friday as its stock reached a new 52-week peak. This substantial ...

Ocugen has captured market attention with a bold regulatory roadmap, announcing plans to submit three gene therapy applications to the ...